Beilinson Friends Forum hosts event for cancer innovation in Israel
A generous endowment from Drs. Susan and Henry Samueli is expected to give cancer treatment and research in Israel an extra leg up.
The Samueli Integrative Cancer Pioneering Institute, named in honor of American donors Susan and Henry Samueli, will be dedicated to innovation in cancer medicine. The progressive center, to be built at Beilinson Hospital in Petah Tikva, was enabled by a $25 million donation by the couple.
The Beilinson Friends Forum hosted the event, together with the Friends of Rabin Medical Center and Beilinson and Hasharon Hospitals, at Tel Aviv’s Hilton Hotel in the presence of the donating couple, hundreds of guests and medical staff, as well as innovators in cancer medicine. They celebrated the inauguration of the Samueli Integrative Cancer Pioneering Institute as a potential turning point in cancer treatment.
The event also held a panel discussion, entitled “Invention: Ingenuity or Opportunity?” The panel was led by Prof. Gal Markel, of Tel Aviv University, an oncology specialist, and the chief scientist of S Sheba Hospital’s Ella Lemelbaum Institute for Immuno-Oncology.
Other panelists included the co-founder and CEO of Beyond Biologics, Dr. Tehila Ben Moshe, Reichman University provost Prof. Varda Liberman, and Prof. Elyakim Rubinstein, former vice president of the Supreme Court. Henry Samueli also participated in the panel discussion.
Pini Cohen, chairman of the Friends of Rabin Medical Center, said “I feel great pride in being part of the special family of Rabin Medical Center and its friends – a family that turns a vision into saving lives; a family that pulsates with the Israeli and humane spirit of caring and generosity; a family that to be a part of, is to see Israel at its best.”
He further emphasized the massive benefits provided by the Samuelis’ donation, saying “the Samueli Institute is the medicine of tomorrow – and also the critical need of today, and there is no hospital more worthy of leading this mission than Rabin Medical Center.
“This is a rare contribution in its scope, and in combination with the support of Clalit [health fund], we will be capable of producing meteoric progress in the field of cancer. The Clalit databases are among the largest in the world and allow us extensive studies that will lead to breakthroughs on a global scale,” said Dr. Eytan Wirtheim, CEO of Rabin Medical Center. “Thanks to this donation, Beilinson becomes a trailblazer for all medical centers in Israel.
Jerusalem Post Store
`; document.getElementById("linkPremium").innerHTML = cont; var divWithLink = document.getElementById("premium-link"); if (divWithLink !== null && divWithLink !== 'undefined') { divWithLink.style.border = "solid 1px #cb0f3e"; divWithLink.style.textAlign = "center"; divWithLink.style.marginBottom = "15px"; divWithLink.style.marginTop = "15px"; divWithLink.style.width = "100%"; divWithLink.style.backgroundColor = "#122952"; divWithLink.style.color = "#ffffff"; divWithLink.style.lineHeight = "1.5"; } } (function (v, i) { });